Nanobac Pharmaceuticals Inc. (NNBP)

Overview

Nanobac Pharmaceuticals, Incorporated, initially known as HealthCentrics Inc., underwent a name change in December 2002, marking a significant pivot in its focus towards advancing human health through innovative means. Established in 1994 and headquartered in Tampa, Florida, this groundbreaking entity has carved a niche in the healthcare industry. It specializes in the discovery and development of a diverse range of products and services, specifically targeting the detection and treatment of calcifying nanoparticles (CNPs). These minute particles are implicated in various disease processes, and Nanobac Pharmaceuticals leverages cutting-edge science to combat their adverse health effects. The company's holistic approach spans from diagnostic solutions to therapeutic interventions, addressing complex medical conditions across urology and cardiology. Through its commitment to research and clinical studies, Nanobac Pharmaceuticals aims to lead the charge in mitigating the impact of chronic diseases and improving patient outcomes.

Products and Services

Nanobac Pharmaceuticals offers a comprehensive portfolio of products and services designed for the effective detection and management of diseases associated with calcifying nanoparticles (CNPs). Their groundbreaking work in this area has led to the development of several key diagnostic tools and therapeutic solutions.

• NANO-CAPTURE

This in vitro diagnostic (IVD) kit serves as a cornerstone for detecting CNPs, enabling healthcare providers to identify the presence of these nanoparticles in patients. The NANO-CAPTURE kit employs sophisticated technologies to ensure accurate and reliable results, making it a critical tool in the diagnosis and monitoring of conditions linked with CNPs.

• NANO-SERO

Complementing the NANO-CAPTURE kit, the NANO-SERO assay provides a detailed serological assessment, offering insights into the body's response to CNPs. This assay facilitates a deeper understanding of the immune system's interaction with calcifying nanoparticles, which is pivotal in developing targeted treatment strategies and monitoring disease progression.

• Assays, Antibodies, and Reagents

Beyond diagnostic kits, Nanobac Pharmaceuticals manufactures and markets a broad selection of assays, antibodies, and reagents specially formulated for detecting and studying CNPs. These products are indispensable tools for researchers and clinicians, supporting ongoing efforts to uncover the pathological roles of CNPs and exploring potential therapeutic avenues.

• Research and Clinical Studies

The company's dedication to innovation extends into the realm of research and clinical studies, with a strong emphasis on urological and cardiovascular diseases. Through these initiatives, Nanobac Pharmaceuticals is at the forefront of investigating the implications of CNPs in conditions such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, polycystic kidney diseases, and cardiovascular diseases. The insights gained from this research are instrumental in the development of novel diagnostics and therapies, ultimately contributing to the advancement of medical science and patient care.